Pharmaceuticals

Esperion Therap

Esperion Therapeutics released FY2026 Q1 earnings on May 8 Pre-Market (EST), actual revenue USD 80.1 M (forecast USD 84.52 M), actual EPS USD -0.1002 (forecast USD -0.03)

BioPharma Credit PLC Announces Financing Allocation for Esperion Transaction

Needham Analyst Downgrades Esperion to Hold

Archimed to Take Over Esperion Therapeutics for up to $1.1 Billion

Esperion Therapeutics to Release FY2026 Q1 Earnings on May 7, Pre-Market EST; Forecast Revenue USD 84.52M, EPS USD -0.03

Esperion Completes Corstasis Acquisition

Esperion Therapeutics released FY2025 earnings on March 10 Pre-Market (EST), actual revenue USD 403.14 M (forecast USD 402.1 M), actual EPS USD -0.1091 (forecast USD -0.0616)

Esperion Therapeutics released FY2025 Q4 earnings on March 10 Pre-Market (EST), actual revenue USD 168.45 M (forecast USD 166.12 M), actual EPS USD 0.2172 (forecast USD 0.2716)

Esperion Therapeutics to Release FY2025 Q4 Earnings on March 10, Pre-Market EST; Forecast Revenue USD 165.12 M, EPS USD 0.2742

Piper Sandler Upgrades Esperion Therapeutics to Overweight with $9 Price Target

Esperion Therapeutics and Otsuka launch NEXLETOL® in Japan

Esperion Therapeutics partner HLS Therapeutics announces NILEMDO® approval in Canada

US Bank Maintains Esperion Sell Rating and Raises Target Price

Esperion Reports New Data on NEXLETOL Cardiovascular Efficacy at Scientific Meeting

Esperion Therapeutics released FY2025 9 Months Earnings on November 6 Pre-Market EST, with actual revenue of USD 234.69 M and actual EPS of USD -0.4267

Esperion Therapeutics released FY2025 Q3 earnings on November 6 Pre-Market (EST), actual revenue USD 87.31 M (forecast USD 77.2 M), actual EPS USD -0.156 (forecast USD -0.0782)

Esperion Therapeutics to Release FY2025 Q3 Earnings on November 6, Pre-Market EST; Forecast Revenue USD 77.8 M, EPS USD -0.065

Esperion Therapeutics Shares Rise Despite Volume Decline, Reporting Better-than-Expected Quarterly Earnings

Analysts Maintain Buy Rating on Esperion with Specific Price Targets

Esperion Therapeutics Inc. Nominates ESP-2001 for Primary Sclerosing Cholangitis Preclinical Development

Freecast

Cuprina

U-BX Tech

HORIZON SPACE ACQUISITION II CORP COM USD0.0001 30/03/2026(SUB/RIGHTS)

Defiance Pure Space Dly 2X Strat ETF

VS MEDIA

Everbright Digital

Park Ha Biological Tech

Friedman Industries

Defiance Daily Target 2X Short ASTS ETF

ESPR

Esperion Therapeutics received clearance from the German Bundeskartellamt for its merger with Essence Parent Inc. The company is now preparing for a virtual stockholder vote scheduled for July 8, 2026. While this regulatory hurdle is cleared, the transaction still requires completion of HSR waiting periods and final stockholder approval to close.

TradingView

Esperion cleared for merger by German antitrust authority; stockholder vote set for July 8

Esperion Therapeutics (ESPR) has highlighted significant uncertainty in its 10-Q filing, emphasizing that forward-looking statements regarding finances and operations are inherently uncertain. This raises investor risk as actual results may differ materially from projections, influenced by internal and external factors. The firm’s performance could vary significantly, affecting valuation models and stakeholder confidence. Currently, Wall Street holds a consensus rating of Hold on ESPR stock, with 1 Sell and 6 Holds.

Tip Ranks

Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk

Esperion (ESPR) advanced clinical programs in 2024–2025, including a pediatric trial, and secured expanded indications and international approvals to support broader market access for its products.1Esperion (ESPR) saw mean earnings estimates plunge about 781.6% over three months; one analyst cut their estimate in the past 30 days.2

Key facts: Esperion Expands 2024–25 Programs; Estimates Fall 781.6%

SILA

CRBG

Class Action Attorney Juan Monteverde of Monteverde & Associates PC is investigating mergers involving Esperion Therapeutics (ESPR), Sila Realty Trust (SILA), Corebridge Financial (CRBG), and Equitable Holdings (EQH). Shareholders of Esperion are expected to receive $3.16 per share, while Sila Realty shareholders will get $30.38 per share. Corebridge and Equitable will merge, with Corebridge shareholders owning 51% and Equitable shareholders 49% of the combined entity. The firm has a successful track record in recovering funds for shareholders and offers free consultations.

prnewswire

Equitable

Sila Realty Trust

Corebridge Financial

Corebridge Financial, Inc.

EQUITABLE HOLDINGS INC 5.25% DEP RP 1/1000 NON CM PERP PRF SR A

EQUITABLE HOLDINGS INC DEP SHS REPSTG 1/1000TH PERP PFD SER C

14:27 ETSHAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--ESPR, SILA, CRBG, and EQH

Esperion (ESPR) has been downgraded to a Hold rating by Needham analyst Serge Belanger, who set a price target of $3.22. Belanger, a 5-star analyst with a 12.8% average return and 49.40% success rate, focuses on the Healthcare sector. The current analyst consensus for Esperion remains a Hold.

Viridian Therapeutics

Cormedix

Esperion (ESPR) was downgraded to a Hold Rating at Needham

GBTG

Halper Sadeh LLC is investigating potential violations of federal securities laws by Esperion Therapeutics, Global Business Travel Group, Modiv Industrial, and ACRES Commercial Realty. The firm is concerned that insiders may benefit financially at the expense of ordinary shareholders. Shareholders are encouraged to contact the firm for legal rights and options regarding the proposed transactions, which may limit competing offers. Halper Sadeh LLC operates on a contingent fee basis, ensuring no upfront costs for shareholders seeking legal assistance.

Global Business Travel

Modiv Industrial

ACRES Commercial Realty

Global Net Lease

MODIV INDUSTRIAL INC 7.375% CUM RED PERP PFD STOCK SER A

ACRES COMMERCIAL REALTY CORP 7.875% CUM RED PREF SER D

ACRES COMMERCIAL REALTY CORP 8.625% CUM RED FXD TO FLOATING PRF SER C

GLOBAL NET LEASE INC 7.25% CUM RED PFRD STOCK SER A USD25

GLOBAL NET LEASE INC 7.375% CUM RED PER PFRD STOCK SER E

GLOBAL NET LEASE INC 7.50% CUM RED PER PFRD STOCK SER D

GLOBAL NET LEASE INC 6.875% CUM RED PER PFD SHS SER B USD25.0

14:53 ETAre ESPR, GBTG, MDV, ACR Obtaining Fair Deals for their Shareholders?

Kahn Swick & Foti, LLC is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED funds. Shareholders are set to receive $3.16 per share in cash, along with potential milestone payments. The firm aims to assess whether this offer adequately values the company and the process leading to it. Interested parties can contact KSF for more information regarding their legal rights in this transaction.

MorningStar

Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR

Esperion Therapeutics shares rose on Monday following a $1.1 billion buyout deal with Archimed, offering shareholders $3.16 per share in cash and contingent value rights (CVR) linked to future U.S. sales. The acquisition represents a 58% premium over the stock's closing price on April 30. The CVR includes potential milestone payments based on sales of specific products through 2030. Esperion also recently agreed to acquire Corstasis Therapeutics for $75 million upfront, with additional potential payments totaling up to $180 million.

Esperion Therap(ESPR.US)